Tm Bioscience, Luminex extend partnership to commercialize genetic tests

By Lisa Kerner

Erie, Pa., March 29 - Tm Bioscience Corp. and Luminex Corp. signed a multi-year extension of their partnership agreement, granting Tm rights to commercialize DNA-based molecular diagnostics that operate on Luminex's xMAP technology platform.

The renegotiated agreement incorporates similar terms to the original agreement, including the ability for Tm to distribute Luminex's xMAP systems, including the new LX200 instrument, according to a company news release.

Tm's genetic tests are based on its Tag-It Universal Array platform, while assays from Tm use the Luminex xMAP technology platform for bead-based bioassay multiplexing.

"Tm Bioscience is helping drive our success, having commercialized a broad menu of genetic tests and reagents optimized to run on the Luminex xMAP system, including the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration for diagnostic use in the United States," Luminex president and chief executive officer Patrick J. Balthrop said in the release.

"Molecular diagnostics is an important growth market for Luminex and we are pleased to extend our successful relationship with Tm."

Luminex, based in Austin, Texas, develops, manufactures and markets proprietary biological testing technologies for the life sciences industry.

Located in Toronto, Tm is a DNA-based diagnostics company developing a suite of genetic tests for genetic disorders, drug metabolism and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.